Smoking and COVID-19: A Scoping Review

Chadia Haddad, Sandrella Bou Malhab, Hala Sacre, Pascale Salameh, Chadia Haddad, Sandrella Bou Malhab, Hala Sacre, Pascale Salameh

Abstract

Smoking affects a person's overall health and damages nearly every organ of the body. Since smoking tobacco affects and damages the lungs, it increases the risk of respiratory infections and makes it easier for the coronavirus disease (COVID-19) to invade the lung tissue, causing more severe symptoms and increasing the risk of death. However, debates are still ongoing as to the effect of cigarette smoking on vulnerability to COVID-19. Some studies, where active smokers were underrepresented among patients with COVID-19, claimed that a "smoker's paradox" may exist in COVID-19 and that smokers are protected from infection and severe complications of COVID-19. However, other studies reported the opposite trend. The objective of this study is to review the findings of epidemiological and in vitro studies about the association between smoking and the risk of contracting COVID-19, taking into account disease severity. Several epidemiological studies have found a higher smoking prevalence among COVID-19 infected patients. Also, studies had shown that people with respiratory diseases caused by tobacco use are at higher risk of developing severe COVID-19 symptoms. Studies have shown that in vitro, the acute exposure allows for more severe proximal airway epithelial disease from SARS-CoV-2 by reducing the mucosal innate immune response and the proliferation of airway basal stem cells and has implications for disease spread and severity in people exposed to cigarette smoke, with a more severe viral infection and cell death. Smoker patients with different comorbidities are at higher risk of contracting the COVID-19 virus and have a worse prognosis for the virus as well as for their comorbidities. Further investigations of the interaction between smoking and COVID-19 are warranted to accurately assess the risk of contracting COVID-19 among smokers, and the progression to mechanical ventilation or death in patients who suffer from it.

Keywords: Smoking; cigarette smoking; coronavirus disease; epidemiologic studies; tobacco waterpipe.

Conflict of interest statement

Declaration of Conflicting Interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

© The Author(s) 2021.

References

    1. Bommele J, Hopman P, Walters BH, et al. The double-edged relationship between COVID-19 stress and smoking: implications for smoking cessation. Tob Induc Dis. 2020;18:63.
    1. Kowitt SD, Cornacchione Ross J, Jarman KL, et al. Tobacco quit intentions and behaviors among cigar smokers in the United States in response to COVID-19. Int J Environ Res Public Health. 2020;17:5368.
    1. Caponnetto P, Inguscio L, Saitta C, Maglia M, Benfatto F, Polosa R. Smoking behavior and psychological dynamics during COVID-19 social distancing and stay-at-home policies: a survey. Health Psychol Res. 2020;8:9124.
    1. Sun Y, Li Y, Bao Y, et al. Brief report: increased addictive internet and substance use behavior during the COVID-19 pandemic in China. Am J Addict. Published online June 4, 2020. doi:10.1111/ajad.13066
    1. Patwardhan P. COVID-19: risk of increase in smoking rates among England’s 6 million smokers and relapse among England’s 11 million ex-smokers. BJGP open. 2020;4:bjgpopen20X101067.
    1. Chertok IRA. Perceived risk of infection and smoking behavior change during COVID-19 in Ohio. Public Health Nurs. Published online September 27, 2020. doi:10.1111/phn.12814
    1. Ahmed N, Maqsood A, Abduljabbar T, Vohra F. Tobacco smoking a potential risk factor in transmission of COVID-19 infection. Pak J Med Sci. 2020;36: S104-S107.
    1. Van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382:1564-1567.
    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-733.
    1. World Health Organization. Modes of Transmission of Virus Causing COVID-19: Implications for IPC Precaution Recommendations: Scientific Brief, 27 March 2020. World Health Organization; 2020.
    1. Sabino-Silva R, Jardim ACG, Siqueira WL. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis. Clin Oral Investig. 2020;24:1619-1621.
    1. Ranieri M. COVID-19 self-infection in cigarette smoking: description of the mechanism. Preprint. doi:10.13140/RG.2.2.15310.00321 2020
    1. Alagaili AN, Briese T, Amor NM, Mohammed OB, Lipkin WI. Waterpipe smoking as a public health risk: potential risk for transmission of MERS-CoV. Saudi J Biol Sci. 2019;26:938-941.
    1. World Health Organization. Knowledge hub for waterpipe tobacco smoking. Increased risk of COVID-19 infection amongst smokers and amongst waterpipe users. 2020. Accessed August 25, 2020
    1. Shekhar S, Hannah-Shmouni F. Hookah smoking and COVID-19: call for action. CMAJ. 2020;192:E462-E462.
    1. Maziak W, Taleb ZB, Bahelah R, et al. The global epidemiology of waterpipe smoking. Tob control. 2015;24(suppl 1):i3-i12.
    1. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19). Community mitigation resources; 2020. Accessed August 25, 2020
    1. World Health Organization. Tobacco Free initiative. Tobacco and waterpipe use increases the risk of COVID-19. 2020. Accessed August 25, 2020
    1. Oakes JM, Fuchs RM, Gardner JD, Lazartigues E, Yue X. Nicotine and the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol. 2018;315:R895-R906.
    1. Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). Multidisciplinary Digital Publishing Institute; 2020.
    1. Changeux J-P, Amoura Z, Rey FA, Miyara M. A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. C R Biol. 2020;343:33-39.
    1. de Man FS, Tu L, Handoko ML, et al. Dysregulated renin–angiotensin–aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186:780-789.
    1. Jia H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock. 2016;46:239-248.
    1. Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp physiol. 2008;93:543-548.
    1. Han S-X, He G-M, Wang T, et al. Losartan attenuates chronic cigarette smoke exposure-induced pulmonary arterial hypertension in rats: possible involvement of angiotensin-converting enzyme-2. Toxicol Appl Pharmacol. 2010;245:100-107.
    1. Bruce E, Shenoy V, Rathinasabapathy A, et al. Selective activation of angiotensin AT 2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis. Br. J. Pharmacol. 2015;172:2219-2231.
    1. Alwis KU, deCastro BR, Morrow JC, Blount BC. Acrolein exposure in US tobacco smokers and non-tobacco users: NHANES 2005–2006. Environ Health Perspect. 2015;123:1302-1308.
    1. Borgas D, Chambers E, Newton J, et al. Cigarette smoke disrupted lung endothelial barrier integrity and increased susceptibility to acute lung injury via histone deacetylase 6. Am J Respir Cell Mol Biol. 2016;54:683-696.
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.
    1. Barua RS, Ambrose JA, Srivastava S, DeVoe MC, Eales-Reynolds L-J. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: an in vitro demonstration in human coronary artery endothelial cells. Circulation. 2003;107:2342-2347.
    1. Gonçalves R, Coletta R, Silvério K, et al. Impact of smoking on inflammation: overview of molecular mechanisms. Inflamm Res. 2011;60:409-424.
    1. Qiu F, Liang C-L, Liu H, et al. Impacts of cigarette smoking on immune responsiveness: up and down or upside down? Oncotarget. 2017;8:268.
    1. Cloëz-Tayarani I, Changeux JP. Nicotine and serotonin in immune regulation and inflammatory processes: a perspective. J Leukoc Biol. 2007;81:599-606.
    1. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002;2:372-377.
    1. Cui W-Y, Li MD. Nicotinic modulation of innate immune pathways via α7 nicotinic acetylcholine receptor. J Neuroimmune Pharmacol. 2010;5:479-488.
    1. Steven S, Frenis K, Oelze M, et al. Vascular inflammation and oxidative stress: major triggers for cardiovascular disease. Oxid Med Cell Longev. 2019;2019:7092151.
    1. Qasim H, Alarabi AB, Alzoubi KH, Karim ZA, Alshbool FZ, Khasawneh FT. The effects of hookah/waterpipe smoking on general health and the cardiovascular system. Environ Health Prev Med. 2019;24:1-17.
    1. Sun L, Liu C, Xu X, et al. Ambient fine particulate matter and ozone exposures induce inflammation in epicardial and perirenal adipose tissues in rats fed a high fructose diet. Part Fibre Toxicol. 2013;10:1-20.
    1. Piantadosi CA. Carbon monoxide, reactive oxygen signaling, and oxidative stress. Free Radic Biol Med. 2008;45:562-569.
    1. Ercal N, Gurer-Orhan H, Aykin-Burns N. Toxic metals and oxidative stress part I: mechanisms involved in metal-induced oxidative damage. Curr Top Med Chem. 2001;1:529-539.
    1. Sui Y-B, Chang J-R, Chen W-J, et al. Angiotensin-(1-7) inhibits vascular calcification in rats. Peptides. 2013;42:25-34.
    1. Moghe A, Ghare S, Lamoreau B, et al. Molecular mechanisms of acrolein toxicity: relevance to human disease. Toxicol Sci. 2015;143:242-255.
    1. Dvorakova M, Lips KS, Brüggmann D, Slavikova J, Kuncova J, Kummer W. Developmental changes in the expression of nicotinic acetylcholine receptor α-subunits in the rat heart. Cell Tissue Res. 2005;319:201-209.
    1. Meurrens K, Ruf S, Ross G, Schleef R, von Holt K, Schlüter K-D. Smoking accelerates the progression of hypertension-induced myocardial hypertrophy to heart failure in spontaneously hypertensive rats. Cardiovasc Res. 2007;76:311-322.
    1. Colombo ES, Davis J, Makvandi M, et al. Effects of nicotine on cardiovascular remodeling in a mouse model of systemic hypertension. Cardiovasc Toxicol. 2013;13:364-369.
    1. Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2004;24:429-434.
    1. Tweed JO, Hsia SH, Lutfy K, Friedman TC. The endocrine effects of nicotine and cigarette smoke. Trends Endocrinol Metab. 2012;23334-342.
    1. Wang X, Yang Z, Xue B, Shi H. Activation of the cholinergic antiinflammatory pathway ameliorates obesity-induced inflammation and insulin resistance. Endocrinology. 2011;152:836-846.
    1. Tatebe J, Morita T. Enhancement of TNF-α expression and inhibition of glucose uptake by nicotine in the presence of a free fatty acid in C2C12 skeletal myocytes. Horm Metab Res. 2011;43:11-16.
    1. Bruin JE, Gerstein HC, Holloway AC. Long-term consequences of fetal and neonatal nicotine exposure: a critical review. Toxicol Sci. 2010;116:364-374.
    1. US Department of Health and Human Services. How Tobacco Smoke Causes Disease: What It Means To You. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010.
    1. US Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. US Department of Health and Human Services, Centers for Disease Control and Prevention; 2014.
    1. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Centers for Disease Control Prevention; 2010.
    1. Nemmar A, Al-Salam S, Yuvaraju P, Beegam S, Yasin J, Ali BH. Chronic exposure to water-pipe smoke induces alveolar enlargement, DNA damage and impairment of lung function. Cell Physiol Biochem. 2016;38:982-992.
    1. Iyanda AE, Adeleke R, Lu Y, et al. A retrospective cross-national examination of COVID-19 outbreak in 175 countries: a multiscale geographically weighted regression analysis (January 11-June 28, 2020). J Infect Public Health. 2020;13:1438-1445.
    1. Yannouchos T, Sussman R, Mier JM, Poulas K, Farsalinos K. Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory-confirmed COVID-19 cases. Eur Respir J. 2020;2002144.
    1. Tsigaris P, Teixeira da, Silva JA. Smoking prevalence and COVID-19 in Europe. Nicotine Tob Res. 2020;22:1646-1649.
    1. Tajlil A, Ghaffari S, Pourafkari L, Mashayekhi S, Roshanravan N. Nicotine and smoking in the COVID-19 era. J Cardiovasc Thorac Res. 2020;12:136.
    1. Cattaruzza M, Zagà V, Gallus S, D’Argenio P, Gorini G. Tobacco smoking and COVID-19 pandemic: old and new issues. A summary of the evidence from the scientific literature. Acta Biomed. 2020;91:106-112.
    1. Usman MS, Siddiqi TJ, Khan MS, et al. Is there a smoker’s paradox in COVID-19? BMJ Evid Based Med. 2020.
    1. Farsalinos K, Barbouni A, Niaura R. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Intern Emerg Med. 2020;15:845-852.
    1. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med. 2020;8:e35.
    1. Jackson SE, Brown J, Shahab L, Steptoe A, Fancourt D. COVID-19, smoking and inequalities: a study of 53 002 adults in the UK. Tob Control. 2020.
    1. Miyara M, Tubach F, Pourcher V, Morelot-Panzini C, Pernet J, Haroche J. Low rate of daily active tobacco smoking in patients with symptomatic cOvID-19. Qeios. Published online May 2020.
    1. Gaiha SM, Cheng J, Halpern-Felsher B. Association between youth smoking, electronic cigarette use, and Coronavirus Disease 2019. J Adolesc Health. 2020;67:519-523.
    1. Grundy EJ, Suddek T, Filippidis FT, Majeed A, Coronini-Cronberg S. Smoking, SARS-CoV-2 and COVID-19: a review of reviews considering implications for public health policy and practice. Tob Induc Dis. 2020;18:58.
    1. Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.
    1. Liu W, Tao Z-W, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J. 2020;133:1032-1038.
    1. Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One. 2020;15:e0233147.
    1. Cen Y, Chen X, Shen Y, et al. Risk factors for disease progression in mild to moderate COVID-19 patients–a multi-center observational study. Clin Microbiol Infect. 2020;26:1242-1247.
    1. Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine Tob Res. 2020;22:1653-1656.
    1. Almazeedi S, Al-Youha S, Jamal MH, et al. Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait. EClinicalMedicine. 2020;24:100448.
    1. Jehi L, Ji X, Milinovich A, et al. Development and validation of a model for individualized prediction of hospitalization risk in 4,536 patients with COVID-19. PLoS One. 2020;15:e0237419.
    1. Soares RdCM, Mattos LR, Raposo LM. Risk factors for hospitalization and mortality due to COVID-19 in Espirito Santo State, Brazil. Am J Trop Med Hyg. 2020;103:1184-1190.
    1. Zhao Z, Chen A, Hou W, et al. Prediction model and risk scores of ICU admission and mortality in COVID-19. PLoS One. 2020;15:e0236618.
    1. Luo J, Rizvi H, Preeshagul IR, et al. COVID-19 in patients with lung cancer. Ann Oncol. 2020;31:1386-1396.
    1. Archie SR, Cucullo L. Cerebrovascular and neurological dysfunction under the threat of COVID-19: is there a comorbid role for smoking and vaping? Int J Mol Sci. 2020;21:3916.
    1. Parra-Bracamonte G, Lopez-Villalobos N, Parra-Bracamonte F. Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large dataset from Mexico. Ann Epidemiol. 2020;52:93-98.e2.
    1. Curigliano G. Cancer patients and risk of mortality for COVID-19. Cancer Cell. 2020;38:161-163.
    1. Sanchez-Ramirez DC, Mackey D. Underlying respiratory diseases, specifically COPD, and smoking are associated with severe COVID-19 outcomes: a systematic review and meta-analysis. Respir Med. 2020;171:106096.
    1. Farsalinos K, Barbouni A, Poulas K, Polosa R, Caponnetto P, Niaura R. Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2020;11:2040622320935765.
    1. Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: a living rapid evidence review. Addiction. 2020.
    1. Leung JM, Sin DD. Smoking, ACE-2, and COVID-19: ongoing controversies. Eur Respir J. 2020;56:2001759.
    1. Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging. 2020;12:10087-10098.
    1. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.e8.
    1. Porzionato A, Emmi A, Barbon S, et al. Sympathetic activation: a potential link between comorbidities and COVID-19. FEBS J. 2020;287:3681-3688.
    1. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8:782-792.
    1. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109:531-538.
    1. Sardu C, D’Onofrio N, Balestrieri ML, et al. Outcomes in patients with hyperglycemia affected by Covid-19: can we do more on glycemic control? Diabetes Care. 2020;43:1408-1415.
    1. Scheen AJ, Marre M, Thivolet C. Prognostic factors in patients with diabetes hospitalized for COVID-19: findings from the CORONADO study and other recent reports. Diabetes Metab. 2020;46:265-271.
    1. Iacobellis G, Penaherrera CA, Bermudez LE, Mizrachi EB. Admission hyperglycemia and radiological findings of SARS-COv2 in patients with and without diabetes. Diabetes Res Clin Pract. 2020;164:108185.
    1. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94:e00127-20.
    1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-513.
    1. Münzel T, Hahad O, Kuntic M, Keaney JF, Deanfield JE, Daiber A. Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes. Eur Heart J. 2020;41:4057-4070.
    1. Purkayastha A, Sen C, Garcia G, et al. Direct exposure to SARS-CoV-2 and cigarette smoke increases infection severity and alters the stem cell-derived airway repair response. Cell Stem Cell. 2020;27:869-875.e4.
    1. Kaur G, Lungarella G, Rahman I. SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping. J Inflamm. 2020;17:21.
    1. Voinsky I, Gurwitz D. Smoking and COVID-19: similar bronchial ACE2 and TMPRSS2 expression and higher TMPRSS4 expression in current versus never smokers. Drug Dev Res. Published online August 5, 2020.doi:10.1002/ddr.21729
    1. Smith JC, Sausville EL, Girish V, et al. Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract. Dev Cell. 2020;53:514–529.e3.
    1. Chakladar J, Shende N, Li WT, Rajasekaran M, Chang EY, Ongkeko WM. Smoking-mediated upregulation of the androgen pathway leads to increased SARS-CoV-2 susceptibility. Int J Mol Sci. 2020;21:3627.
    1. Magleby R, Westblade LF, Trzebucki A, et al. Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019. Clin Infect Dis. Published online June 30, 2020.doi:10.1093/cid/ciaa851
    1. Komiyama M, Hasegawa K. Smoking cessation as a public health measure to limit the coronavirus disease 2019 pandemic. Eur Cardiol. 2020;15:e16.
    1. Kamiński M, Muth A, Bogdański P. Smoking, vaping, and tobacco industry during COVID-19 pandemic: Twitter data analysis. Cyberpsychol Behav Soc Netw. 2020;23:811-817.
    1. Seiler NK, Swamy R, Xiao J, Yun Y. Tobacco smoking cessation in mental health services during the COVID-19 pandemic. J Addict Dis. 2020;38:582-584.
    1. Boutou AK, Pitsiou G, Kontakiotis T, Kioumis I. Nicotine treatment and smoking cessation in the era of COVID-19 pandemic: an interesting alliance. ERJ Open Res. 2020;6:00306-2020.
    1. Tetik BK, Tekinemre IG, Taş S. The effect of the COVID-19 pandemic on smoking cessation success. J Community Health. Published online July 8, 2020.doi:10.1007/s10900-020-00880-2
    1. Klemperer EM, West JC, Peasley-Miklus C, Villanti AC. Change in tobacco and electronic cigarette use and motivation to quit in response to COVID-19. Nicotine Tob Res. 2020;22:1662-1663.
    1. Tizabi Y, Getachew B, Copeland RL, Aschner M. Nicotine and the nicotinic cholinergic system in COVID-19. FEBS J. 2020;287:3656-3663.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir